Please wait
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April
2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
29
April 2026 - “Haleon 2026 Q1 Trading
Statement”
|
|
|
|
99.1
Haleon plc: 2026 Q1 Trading Statement
29 April 2026: Haleon plc
(the "Company" or "Haleon") today announces its Q1
trading statement for the year ending 31 December 2026 is available
at:
http://www.rns-pdf.londonstockexchange.com/rns/2888C_1-2026-4-28.pdf .
The Q1 trading statement will also be available on the Haleon
website www.haleon.com/investors,
and has been submitted in full unedited text to the Financial
Conduct Authority's National Storage Mechanism and will shortly be
available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Presentation for analysts and shareholders
A short presentation followed by Q&A will be hosted by Brian
McNamara, Chief Executive Officer, and Dawn Allen, Chief Financial
Officer at 9:00am BST (10:00am CEST) on 29 April 2026, which can be
accessed at www.haleon.com/investors/.
For analysts and shareholders wishing to ask questions on the
Q&A call, please use the dial-in details below which will have
a Q&A facility:
|
UK:
|
+44 (0) 808 189
0158
|
|
US:
|
+1 855 979 6654
|
|
All other:
|
+44 (0) 203 936 2999
|
|
Passcode:
|
975813
|
An archived webcast of the Q&A call will be available later on
the day of the results and can be accessed
at www.haleon.com/investors.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
|
Jo Russell
|
+44 7787 392441
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Victoria Durman
|
+44 7894 505730
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused
on better everyday health. Our people, our brands, our research,
our investment and our innovation are aimed at improving the
everyday health of consumers. Our product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Our superior brands - such
as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion
consumers and are recommended by health professionals around the
world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date:
April 29, 2026
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
